<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7140116/results/search/disease/results.xml">
  <result pre="in the regulation of the intracellular dNTP pool, linked to" exact="viral" post="restriction, cancer development and autoimmune disorders. SAMHD1 function is"/>
  <result pre="regulation of the intracellular dNTP pool, linked to viral restriction," exact="cancer" post="development and autoimmune disorders. SAMHD1 function is regulated by"/>
  <result pre="intracellular dNTP pool, linked to viral restriction, cancer development and" exact="autoimmune" post="disorders. SAMHD1 function is regulated by phosphorylation through a"/>
  <result pre="to boost chemotherapeutic regimens. The evaluation of SAMHD1 expression in" exact="cancer" post="tissues allowed for the identification of cancer types that"/>
  <result pre="SAMHD1 expression in cancer tissues allowed for the identification of" exact="cancer" post="types that would benefit from the pharmacological modulation of"/>
  <result pre="improvement of current antimetabolite-based treatments. SAMHD1 antimetabolite CDK4/6 pemetrexed HIV" exact="cancer" post="1. Introduction Sterile alpha motif and histidine-aspartic acid domain-containing"/>
  <result pre="in SAMHD1 were first identified as being causative of Aicardi–Goutieres" exact="syndrome" post="(AGS), a severe autoimmune disease [3], but later it"/>
  <result pre="identified as being causative of Aicardi–Goutieres syndrome (AGS), a severe" exact="autoimmune" post="disease [3], but later it was proposed as a"/>
  <result pre="as being causative of Aicardi–Goutieres syndrome (AGS), a severe autoimmune" exact="disease" post="[3], but later it was proposed as a tumor"/>
  <result pre="autoimmune disease [3], but later it was proposed as a" exact="tumor" post="suppressor gene, since mutations in SAMHD1 are associated with"/>
  <result pre="since mutations in SAMHD1 are associated with different types of" exact="cancer" post="[4,5] and its expression has been found to be"/>
  <result pre="More recently, SAMHD1 has been implicated in the protection against" exact="cancer" post="and chronic inflammation by limiting the release of single-stranded"/>
  <result pre="SAMHD1 has been implicated in the protection against cancer and" exact="chronic" post="inflammation by limiting the release of single-stranded DNA [8]."/>
  <result pre="release of single-stranded DNA [8]. SAMHD1 also acts as a" exact="viral" post="restriction factor, limiting the permissiveness of cells to diverse"/>
  <result pre="of cells to diverse viruses (reviewed in [9]), including human" exact="immunodeficiency" post="virus (HIV-1) [10,11]. SAMHD1 inhibits retroviral replication at the"/>
  <result pre="dNTP below the threshold required for reverse transcription of the" exact="viral" post="RNA genome into DNA [10,11]. SAMHD1 activity is counteracted"/>
  <result pre="been shown to block SAMHD1 phosphorylation, inducing SAMHD1 function and" exact="viral" post="restriction [16,17,18,19,20]. Nucleoside analogues are commonly used in the"/>
  <result pre="[16,17,18,19,20]. Nucleoside analogues are commonly used in the treatment of" exact="viral" post="infections and cancer [21]. Following phosphorylation by intracellular kinases,"/>
  <result pre="Nucleoside analogues are commonly used in the treatment of viral" exact="infections" post="and cancer [21]. Following phosphorylation by intracellular kinases, these"/>
  <result pre="are commonly used in the treatment of viral infections and" exact="cancer" post="[21]. Following phosphorylation by intracellular kinases, these analogues are"/>
  <result pre="[30,31], including cytarabine (Cytosar-U®,Ara-C), a first line therapeutic agent for" exact="acute" post="myelogenous leukaemia (AML) and SAMHD1 expression levels were negatively"/>
  <result pre="cytarabine (Cytosar-U®,Ara-C), a first line therapeutic agent for acute myelogenous" exact="leukaemia" post="(AML) and SAMHD1 expression levels were negatively correlated with"/>
  <result pre="2. Results 2.1. SAMHD1 Regulates Antiviral Efficacy of Antimetabolites in" exact="Primary" post="Cells Primary monocyte-derived macrophages (MDMs) are susceptible to HIV-1"/>
  <result pre="2.1. SAMHD1 Regulates Antiviral Efficacy of Antimetabolites in Primary Cells" exact="Primary" post="monocyte-derived macrophages (MDMs) are susceptible to HIV-1 infection, and"/>
  <result pre="differentiation initiates MDM proliferation accompanied by SAMHD1 phosphorylation. Thus, HIV-1" exact="infection" post="of MDM provides an excellent model in which to"/>
  <result pre="Anti-HIV-1 activity of a panel of antimetabolite drugs used in" exact="cancer" post="treatment was evaluated in MDMs in the presence or"/>
  <result pre="cancer treatment was evaluated in MDMs in the presence or" exact="absence of" post="SAMHD1, after transducing cells with HIV-2 Vpx (Figure 1A)."/>
  <result pre="antiviral activity of a panel of antimetabolites currently used in" exact="cancer" post="treatments in wild type or SAMHD1 depleted macrophages. All"/>
  <result pre="specific nucleotide targeted, i.e., purine or pyrimidine, and was not" exact="limited" post="to nucleos(t)ide analogues, as SAMHD1 also affected the efficacy"/>
  <result pre="ribociclib and abemaciclib, was also evaluated in the presence or" exact="absence of" post="SAMHD1. The three agents were tested at the concentration"/>
  <result pre="activity of all three CDK4/6 inhibitors was lost in the" exact="absence of" post="SAMHD1, indicating that the efficacy of CDK4/6 inhibitors depends"/>
  <result pre="inhibitor midostaurin was evaluated (Figure S1A), suggesting that activity of" exact="multiple types" post="of kinase inhibitors may be influenced by SAMHD1 expression."/>
  <result pre="fluorouracil were evaluated alone or in combination with palbociclib in" exact="primary" post="macrophages. Pemetrexed inhibited HIV-1 replication in a dose-dependent manner,"/>
  <result pre="Pemetrexed inhibited HIV-1 replication in a dose-dependent manner, although with" exact="limited" post="potency (EC50 = 0.1 µM, Figure 4A, black line)."/>
  <result pre="synergistic effect observed in drug combinations, were lost in the" exact="absence of" post="SAMHD1, (Figure 4A,B, right panels). Furthermore, the combination of"/>
  <result pre="fluorouracil or the multikinase inhibitor midostaurin with palbociclib showed more" exact="limited" post="effects, i.e., palbociclib partially enhanced the antiviral potency of"/>
  <result pre="calculation indicated synergy at specific concentrations, although CI were 100-fold" exact="lower" post="compared to palbociclib-pemetrexed drug interactions (Table 2) and antagonic"/>
  <result pre="palbociblib in the TZM-bl cell line and in two distinct" exact="breast cancer" post="cell lines, MDA-MB-468 and T47D (Figure S3). As expected,"/>
  <result pre="in the TZM-bl cell line and in two distinct breast" exact="cancer" post="cell lines, MDA-MB-468 and T47D (Figure S3). As expected,"/>
  <result pre="determining palbociclib–antimetabolite drug combination efficacy. 2.5. Alternative Pathways of dNTP" exact="Metabolism" post="Control Are Responsible for Drug Synergy To further explore"/>
  <result pre="combining antimetabolites with the CDK4/6 inhibitor palbociclib, protein expression in" exact="primary" post="macrophages treated with pemetrexed, fluorouracil and palbociclib, alone or"/>
  <result pre="effect is less potent. 2.6. SAMHD1 Is Expressed in Different" exact="Tumor" post="Tissues To further explore the potential value of modulating"/>
  <result pre="further explore the potential value of modulating SAMHD1 function in" exact="cancer" post="patients, we evaluated SAMHD1 expression in different tumor tissues"/>
  <result pre="function in cancer patients, we evaluated SAMHD1 expression in different" exact="tumor" post="tissues by immunohistochemistry (IHC) in paraffin-embedded tissues. SAMHD1 was"/>
  <result pre="paraffin-embedded tissues. SAMHD1 was clearly detected in at least two" exact="cancer" post="tissue types susceptible to being treated with antimetabolites—pancreatic adenocarcinoma"/>
  <result pre="two cancer tissue types susceptible to being treated with antimetabolites—pancreatic" exact="adenocarcinoma" post="and lung large cell carcinoma (Figure 7A,B). In both"/>
  <result pre="tissue types susceptible to being treated with antimetabolites—pancreatic adenocarcinoma and" exact="lung large cell carcinoma" post="(Figure 7A,B). In both cases, SAMHD1 was significantly expressed"/>
  <result pre="types susceptible to being treated with antimetabolites—pancreatic adenocarcinoma and lung" exact="large cell carcinoma" post="(Figure 7A,B). In both cases, SAMHD1 was significantly expressed"/>
  <result pre="to being treated with antimetabolites—pancreatic adenocarcinoma and lung large cell" exact="carcinoma" post="(Figure 7A,B). In both cases, SAMHD1 was significantly expressed"/>
  <result pre="cases, SAMHD1 was significantly expressed in a high percentage of" exact="malignant" post="cells. In addition, IHC data of 17 different types"/>
  <result pre="7C). These results demonstrate that SAMHD1 is expressed in patient" exact="tumor" post="samples but also suggest that modulation of SAMHD1 function"/>
  <result pre="function might be feasible at least in a subgroup of" exact="cancer" post="types. 3. Discussion Nucleotide metabolism plays a central role"/>
  <result pre="metabolism plays a central role in cell proliferation, transformation and" exact="tumor" post="progression [34]. Therefore, inhibition of nucleotide synthesis has been"/>
  <result pre="synthesis has been commonly used in the treatment of cancer," exact="infectious diseases" post="and immune-mediated diseases [34]. By degrading cellular dNTPs, SAMHD1"/>
  <result pre="potency in SAMHD1-expressing cells, whereas nucleoside analogues efficacy was either" exact="limited" post="or enhanced by SAMHD1. Attempts to predict the effect"/>
  <result pre="we hypothesized that compounds whose activity is enhanced in the" exact="absence of" post="SAMHD1 are enzyme substrates. On the contrary, and as"/>
  <result pre="demonstrated for NRTI [23,24,25], compounds that lose activity in the" exact="absence of" post="SAMHD1 would be competing with the intracellular dNTP pool,"/>
  <result pre="would be competing with the intracellular dNTP pool, which is" exact="lower" post="when SAMHD1 is active. Accordingly, anti-folates showed higher activity"/>
  <result pre="nelarabine for T-lymphoblastic lymphoma, cladribine used in the treatment of" exact="hairy cell leukemia" post="and B-cell chronic lymphocytic leukemia, and approved for the"/>
  <result pre="T-lymphoblastic lymphoma, cladribine used in the treatment of hairy cell" exact="leukemia" post="and B-cell chronic lymphocytic leukemia, and approved for the"/>
  <result pre="cladribine used in the treatment of hairy cell leukemia and" exact="B-cell chronic lymphocytic leukemia," post="and approved for the treatment of relapsing-remitting multiple sclerosis."/>
  <result pre="used in the treatment of hairy cell leukemia and B-cell" exact="chronic" post="lymphocytic leukemia, and approved for the treatment of relapsing-remitting"/>
  <result pre="in the treatment of hairy cell leukemia and B-cell chronic" exact="lymphocytic leukemia," post="and approved for the treatment of relapsing-remitting multiple sclerosis."/>
  <result pre="B-cell chronic lymphocytic leukemia, and approved for the treatment of" exact="relapsing-remitting multiple sclerosis." post="On the contrary, SAMHD1 enhances the activity of drugs"/>
  <result pre="chronic lymphocytic leukemia, and approved for the treatment of relapsing-remitting" exact="multiple sclerosis." post="On the contrary, SAMHD1 enhances the activity of drugs"/>
  <result pre="such as floxuridine, most often used in the treatment of" exact="colorectal cancer," post="fluorouracil, used for colon cancer, esophageal cancer, stomach cancer,"/>
  <result pre="used in the treatment of colorectal cancer, fluorouracil, used for" exact="colon cancer," post="esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and"/>
  <result pre="the treatment of colorectal cancer, fluorouracil, used for colon cancer," exact="esophageal cancer," post="stomach cancer, pancreatic cancer, breast cancer, and cervical cancer,"/>
  <result pre="of colorectal cancer, fluorouracil, used for colon cancer, esophageal cancer," exact="stomach cancer," post="pancreatic cancer, breast cancer, and cervical cancer, and anti-folate"/>
  <result pre="cancer, fluorouracil, used for colon cancer, esophageal cancer, stomach cancer," exact="pancreatic cancer," post="breast cancer, and cervical cancer, and anti-folate drugs, such"/>
  <result pre="used for colon cancer, esophageal cancer, stomach cancer, pancreatic cancer," exact="breast cancer," post="and cervical cancer, and anti-folate drugs, such as methotrexate,"/>
  <result pre="cancer, esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and" exact="cervical cancer," post="and anti-folate drugs, such as methotrexate, used against a"/>
  <result pre="used against a number of cancers but also to treat" exact="autoimmune" post="diseases, such as psoriasis, rheumatoid arthritis, and Crohn’s disease,"/>
  <result pre="cancers but also to treat autoimmune diseases, such as psoriasis," exact="rheumatoid arthritis," post="and Crohn’s disease, or pemetrexed, used to treat non-small"/>
  <result pre="and Crohn’s disease, or pemetrexed, used to treat non-small cell" exact="lung cancer" post="[36]. Thus, the data presented here expand the number"/>
  <result pre="Crohn’s disease, or pemetrexed, used to treat non-small cell lung" exact="cancer" post="[36]. Thus, the data presented here expand the number"/>
  <result pre="we cannot rule out the possibility that synergy observed in" exact="breast cancer" post="cell lines might be not entirely dependent on SAMHD1,"/>
  <result pre="cannot rule out the possibility that synergy observed in breast" exact="cancer" post="cell lines might be not entirely dependent on SAMHD1,"/>
  <result pre="of cytotoxic drugs systematically tested in clinical trials that elicited" exact="complete" post="clinical responses as monotherapies, albeit with inevitable relapse [37]."/>
  <result pre="[37]. Combination chemotherapy still constitutes the current paradigm to achieve" exact="systemic" post="disease control in clinical oncology. Thus, our results might"/>
  <result pre="Combination chemotherapy still constitutes the current paradigm to achieve systemic" exact="disease" post="control in clinical oncology. Thus, our results might represent"/>
  <result pre="endocrine therapies is the treatment option in hormone receptor-positive/HER2-negative advanced" exact="breast cancer." post="CDK4/6 inhibitors offer an effective and tolerable treatment that"/>
  <result pre="applied here a screening approach based in anti-HIV-1 activity in" exact="primary" post="macrophages that either express SAMHD1 or do not. Our"/>
  <result pre="is not deregulated and (iv) considers inter-individual differences by using" exact="primary" post="cells from different donors. Indeed, cytotoxicity data obtained in"/>
  <result pre="BC, Canada) as described before [43]. Monocytes were cultured in" exact="complete" post="culture medium: RPMI 1640 medium supplemented with 10% heat-inactivated"/>
  <result pre="medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA), penicillin and streptomycin (Thermo Fisher"/>
  <result pre="Thermo Fisher Scientific, Waltham, MA, USA), penicillin and streptomycin (Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) and differentiated to monocyte derived"/>
  <result pre="streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) and differentiated to" exact="monocyte" post="derived macrophages (MDM) for 4 days in the presence"/>
  <result pre="transfection, supernatants were harvested, filtered and stored at −80 °C." exact="Viral" post="stocks were concentrated using Lenti-X concentrator (Clontech, Mountain View,"/>
  <result pre="concentrator (Clontech, Mountain View, CA, USA). Viruses were titrated by" exact="infection" post="of TZM cells followed by GFP quantification by flow"/>
  <result pre="cells followed by GFP quantification by flow cytometry. 4.4. Virus" exact="Infections" post="MDMs were pretreated with VLP-Vpx for 4h before infection"/>
  <result pre="Virus Infections MDMs were pretreated with VLP-Vpx for 4h before" exact="infection" post="or left with fresh media as a control. Cells"/>
  <result pre="NL4-3-GFP and drugs were added at the time of infection." exact="Viral" post="replication was measured two days later by flow cytometry,"/>
  <result pre="The anti-HIV activity of the different compounds was determined by" exact="infection" post="of cells in the presence of different concentrations of"/>
  <result pre="antibodies were used for immunoblotting: anti-rabbit and anti-mouse horseradish peroxidase-conjugated" exact="secondary" post="antibodies (1:5000; Pierce, Waltham, MA, USA; anti-human Hsp90 (BD"/>
  <result pre="synergic [46]. 4.8. Immunohistochemistry Tissue sections from lung and pancreas" exact="tumor" post="tissues (T2235188-1 and T2235152, respectively, Amsbio UK), were used"/>
  <result pre="respectively, Amsbio UK), were used to evaluate SAMHD1 expression in" exact="tumor" post="tissues ex vivo. All immunohistochemical analyses were performed in"/>
  <result pre="targeted health therapies including nucleoside analogues such as treatments for" exact="cancer" post="and viral infections. Moreover, we show that pharmacological modulation"/>
  <result pre="therapies including nucleoside analogues such as treatments for cancer and" exact="viral" post="infections. Moreover, we show that pharmacological modulation of SAMHD1"/>
  <result pre="cellsProc. Natl. Acad. Sci. USA2013110142721427710.1073/pnas.131203311023858451 3.RiceG.I.BondJ.AsipuA.BrunetteR.L.ManfieldI.W.CarrI.M.FullerJ.C.JacksonR.M.LambT.BriggsT.A.et al.Mutations involved in Aicardi-Goutières" exact="syndrome" post="implicate SAMHD1 as regulator of the innate immune responseNat."/>
  <result pre="immune responseNat. Genet.20094182983210.1038/ng.37319525956 4.CliffordR.LouisT.RobbeP.AckroydS.BurnsA.TimbsA.T.Wright ColopyG.DreauH.SigauxF.JuddeJ.G.et al.SAMHD1 is mutated recurrently in" exact="chronic" post="lymphocytic leukemia and is involved in response to DNA"/>
  <result pre="responseNat. Genet.20094182983210.1038/ng.37319525956 4.CliffordR.LouisT.RobbeP.AckroydS.BurnsA.TimbsA.T.Wright ColopyG.DreauH.SigauxF.JuddeJ.G.et al.SAMHD1 is mutated recurrently in chronic" exact="lymphocytic leukemia" post="and is involved in response to DNA damageBlood20141231021103110.1182/blood-2013-04-49084724335234 5.RentoftM.LindellK.TranP.ChabesA.L.BucklandR.J.WattD.L.MarjavaaraL.NilssonA.K.MelinB.TryggJ.et"/>
  <result pre="Genet.20094182983210.1038/ng.37319525956 4.CliffordR.LouisT.RobbeP.AckroydS.BurnsA.TimbsA.T.Wright ColopyG.DreauH.SigauxF.JuddeJ.G.et al.SAMHD1 is mutated recurrently in chronic lymphocytic" exact="leukemia" post="and is involved in response to DNA damageBlood20141231021103110.1182/blood-2013-04-49084724335234 5.RentoftM.LindellK.TranP.ChabesA.L.BucklandR.J.WattD.L.MarjavaaraL.NilssonA.K.MelinB.TryggJ.et"/>
  <result pre="SilvaS.WangF.HakeT.S.PorcuP.WongH.K.WuL.Downregulation of SAMHD1 expression correlates with promoter DNA methylation in" exact="Sézary syndrome" post="patientsJ. Investig. Dermatol.201413456256510.1038/jid.2013.31123884314 7.WangJ.LuF.ShenX.-Y.WuY.ZhaoL.SAMHD1 is down regulated in lung"/>
  <result pre="of SAMHD1 expression correlates with promoter DNA methylation in Sézary" exact="syndrome" post="patientsJ. Investig. Dermatol.201413456256510.1038/jid.2013.31123884314 7.WangJ.LuF.ShenX.-Y.WuY.ZhaoL.SAMHD1 is down regulated in lung"/>
  <result pre="Sézary syndrome patientsJ. Investig. Dermatol.201413456256510.1038/jid.2013.31123884314 7.WangJ.LuF.ShenX.-Y.WuY.ZhaoL.SAMHD1 is down regulated in" exact="lung cancer" post="by methylation and inhibits tumor cell proliferationBiochem. Biophys. Res."/>
  <result pre="syndrome patientsJ. Investig. Dermatol.201413456256510.1038/jid.2013.31123884314 7.WangJ.LuF.ShenX.-Y.WuY.ZhaoL.SAMHD1 is down regulated in lung" exact="cancer" post="by methylation and inhibits tumor cell proliferationBiochem. Biophys. Res."/>
  <result pre="is down regulated in lung cancer by methylation and inhibits" exact="tumor" post="cell proliferationBiochem. Biophys. Res. Commun.201445522923310.1016/j.bbrc.2014.10.15325449277 8.CoquelF.SilvaM.-J.TécherH.ZadorozhnyK.SharmaS.NieminuszczyJ.MettlingC.DardillacE.BartheA.SchmitzA.-L.et al.SAMHD1 acts at"/>
  <result pre="counteracted by VpxNature201147465465710.1038/nature1011721613998 11.LahouassaH.DaddachaW.HofmannH.AyindeD.LogueE.C.DraginL.BlochN.MaudetC.BertrandM.GrambergT.et al.SAMHD1 restricts the replication of human" exact="immunodeficiency" post="virus type 1 by depleting the intracellular pool of"/>
  <result pre="VpxNature201147465465710.1038/nature1011721613998 11.LahouassaH.DaddachaW.HofmannH.AyindeD.LogueE.C.DraginL.BlochN.MaudetC.BertrandM.GrambergT.et al.SAMHD1 restricts the replication of human immunodeficiency virus" exact="type 1" post="by depleting the intracellular pool of deoxynucleoside triphosphatesNat. Immunol.20121322322810.1038/ni.223622327569"/>
  <result pre="pool of deoxynucleoside triphosphatesNat. Immunol.20121322322810.1038/ni.223622327569 12.HreckaK.HaoC.GierszewskaM.SwansonS.K.Kesik-BrodackaM.SrivastavaS.FlorensL.WashburnM.P.SkowronskiJ.Vpx relieves inhibition of HIV-1" exact="infection" post="of macrophages mediated by the SAMHD1 proteinNature201147465866110.1038/nature1019521720370 13.CribierA.DescoursB.ValadãoA.L.C.LaguetteN.BenkiraneM.Phosphorylation of"/>
  <result pre="Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and" exact="Lymphoid" post="CellsJ. Immunol.20141931988199710.4049/jimmunol.140087325015816 15.WhiteT.E.Brandariz-NuñezA.Valle-CasusoJ.C.AmieS.NguyenL.A.KimB.TuzovaM.Diaz-GrifferoF.The retroviral restriction ability of SAMHD1, but"/>
  <result pre="damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1" exact="infection" post="of macrophagesEMBO J.201837506210.15252/embj.20179688029084722 18.MlcochovaP.SutherlandK.A.WattersS.A.BertoliC.de BruinR.A.RehwinkelJ.NeilS.J.LenziG.M.KimB.KhwajaA.et al.A G1-like state allows"/>
  <result pre="21.JordheimL.P.DurantelD.ZoulimF.DumontetC.Advances in the development of nucleoside and nucleotide analogues for" exact="cancer" post="and viral diseasesNat. Rev. Drug Discov.20131244746410.1038/nrd401023722347 22.BadiaR.PujantellM.Torres-TorronterasJ.Menéndez-AriasL.MartíR.RuzoA.PaulsE.ClotetB.BallanaE.EstéJ.A.et al.SAMHD1 is"/>
  <result pre="the development of nucleoside and nucleotide analogues for cancer and" exact="viral" post="diseasesNat. Rev. Drug Discov.20131244746410.1038/nrd401023722347 22.BadiaR.PujantellM.Torres-TorronterasJ.Menéndez-AriasL.MartíR.RuzoA.PaulsE.ClotetB.BallanaE.EstéJ.A.et al.SAMHD1 is active in"/>
  <result pre="Reverse Transcriptase InhibitorsAntimicrob. Agents Chemother.2014584804481310.1128/AAC.03145-1424913159 24.AmieS.M.DalyM.B.NobleE.SchinaziR.F.BambaraR.A.KimB.Anti-HIV host factor SAMHD1 regulates" exact="viral" post="sensitivity to nucleoside reverse transcriptase inhibitors via modulation of"/>
  <result pre="nucleoside-analogue efficacy against HIV-1 in myeloid cellsSci. Rep.201774282410.1038/srep4282428220857 27.HeroldN.RuddS.G.SanjivK.KutznerJ.BladhJ.PaulinC.B.J.HelledayT.HenterJ.-I.SchallerT.SAMHD1 protects" exact="cancer" post="cells from various nucleoside-based antimetabolitesCell Cycle2017161029103810.1080/15384101.2017.131440728436707 28.HeroldN.RuddS.G.LjungbladL.SanjivK.MyrbergI.H.PaulinC.B.J.HeshmatiY.HagenkortA.KutznerJ.PageB.D.G.et al.Targeting SAMHD1"/>
  <result pre="a biomarker for cytarabine response and a therapeutic target in" exact="acute" post="myeloid leukemiaNat. Med.20172325025510.1038/nm.425527991919 30.KnechtK.M.BuzovetskyO.SchneiderC.ThomasD.SrikanthV.KaderaliL.TofoleanuF.ReissK.FerreirósN.GeisslingerG.et al.The structural basis for cancer"/>
  <result pre="in acute myeloid leukemiaNat. Med.20172325025510.1038/nm.425527991919 30.KnechtK.M.BuzovetskyO.SchneiderC.ThomasD.SrikanthV.KaderaliL.TofoleanuF.ReissK.FerreirósN.GeisslingerG.et al.The structural basis for" exact="cancer" post="drug interactions with the catalytic and allosteric sites of"/>
  <result pre="Inhibitors of SAMHD1PLoS ONE201712e016905210.1371/journal.pone.016905228046007 32.RassidakisG.Z.HeroldN.MyrbergI.H.TsesmetzisN.RuddS.G.HenterJ.-I.SchallerT.NgS.-B.ChngW.J.YanB.et al.Low-level expression of SAMHD1 in" exact="acute" post="myeloid leukemia (AML) blasts correlates with improved outcome upon"/>
  <result pre="of SAMHD1PLoS ONE201712e016905210.1371/journal.pone.016905228046007 32.RassidakisG.Z.HeroldN.MyrbergI.H.TsesmetzisN.RuddS.G.HenterJ.-I.SchallerT.NgS.-B.ChngW.J.YanB.et al.Low-level expression of SAMHD1 in acute" exact="myeloid leukemia" post="(AML) blasts correlates with improved outcome upon consolidation chemotherapy"/>
  <result pre="SAMHD1PLoS ONE201712e016905210.1371/journal.pone.016905228046007 32.RassidakisG.Z.HeroldN.MyrbergI.H.TsesmetzisN.RuddS.G.HenterJ.-I.SchallerT.NgS.-B.ChngW.J.YanB.et al.Low-level expression of SAMHD1 in acute myeloid" exact="leukemia" post="(AML) blasts correlates with improved outcome upon consolidation chemotherapy"/>
  <result pre="with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimensBlood" exact="Cancer" post="J.201889810.1038/s41408-018-0134-z30341277 33.UhlenM.ZhangC.LeeS.SjöstedtE.FagerbergL.BidkhoriG.BenfeitasR.ArifM.LiuZ.EdforsF.et al.A pathology atlas of the human cancer"/>
  <result pre="regimensBlood Cancer J.201889810.1038/s41408-018-0134-z30341277 33.UhlenM.ZhangC.LeeS.SjöstedtE.FagerbergL.BidkhoriG.BenfeitasR.ArifM.LiuZ.EdforsF.et al.A pathology atlas of the human" exact="cancer" post="transcriptomeScience2017357eaan250710.1126/science.aan250728818916 34.AirdK.M.ZhangR.Nucleotide metabolism, oncogene-induced senescence and cancerCancer Lett.201535620421010.1016/j.canlet.2014.01.01724486217 35.HeroldN.RuddS.G.SanjivK.KutznerJ.MyrbergI.H.PaulinC.B.J.OlsenT.K.HelledayT.HenterJ.-I.SchallerT.With"/>
  <result pre="oncogene-induced senescence and cancerCancer Lett.201535620421010.1016/j.canlet.2014.01.01724486217 35.HeroldN.RuddS.G.SanjivK.KutznerJ.MyrbergI.H.PaulinC.B.J.OlsenT.K.HelledayT.HenterJ.-I.SchallerT.With me or against me:" exact="Tumor" post="suppressor and drug resistance activities of SAMHD1Exp. Hematol.201752323910.1016/j.exphem.2017.05.00128502830 36.JoergerM.OmlinA.CernyT.FrühM.The"/>
  <result pre="and mechanism of actionCurr. Drug Targets201011374710.2174/13894501079003097419839929 37.TsesmetzisN.PaulinC.B.J.RuddS.G.HeroldN.Nucleobase and Nucleoside Analogues:" exact="Resistance" post="and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and"/>
  <result pre="of Pharmacokinetics, Pharmacodynamics and MetabolismCancers20181024010.3390/cancers10070240 38.TurnerN.C.RoJ.AndréF.LoiS.VermaS.IwataH.HarbeckN.LoiblS.Huang BartlettC.ZhangK.et al.Palbociclib in Hormone-Receptor-Positive" exact="Advanced" post="Breast CancerN. Engl. J. Med.201537320921910.1056/NEJMoa150527026030518 39.SherrC.J.BeachD.ShapiroG.I.Targeting CDK4 and CDK6:"/>
  <result pre="Pharmacokinetics, Pharmacodynamics and MetabolismCancers20181024010.3390/cancers10070240 38.TurnerN.C.RoJ.AndréF.LoiS.VermaS.IwataH.HarbeckN.LoiblS.Huang BartlettC.ZhangK.et al.Palbociclib in Hormone-Receptor-Positive Advanced" exact="Breast" post="CancerN. Engl. J. Med.201537320921910.1056/NEJMoa150527026030518 39.SherrC.J.BeachD.ShapiroG.I.Targeting CDK4 and CDK6: From"/>
  <result pre="39.SherrC.J.BeachD.ShapiroG.I.Targeting CDK4 and CDK6: From Discovery to TherapyCancer Discov.2016635336710.1158/2159-8290.CD-15-089426658964 40.O’LearyB.FinnR.S.TurnerN.C.Treating" exact="cancer" post="with selective CDK4/6 inhibitorsNat. Rev. Clin. Oncol.20161341743010.1038/nrclinonc.2016.2627030077 41.PatnaikA.RosenL.S.TolaneyS.M.TolcherA.W.GoldmanJ.W.GandhiL.PapadopoulosK.P.BeeramM.RascoD.W.HiltonJ.F.et al.Efficacy"/>
  <result pre="Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with" exact="Breast" post="Cancer, Non-Small Cell Lung Cancer, and Other Solid TumorsCancer"/>
  <result pre="A Changing ParadigmNat. Rev. Cancer2009915316610.1038/nrc260219238148 43.PujantellM.FrancoS.Galván-FemeníaI.BadiaR.CastellvíM.Garcia-VidalE.ClotetB.de CidR.TuralC.MartínezM.A.et al.ADAR1 affects HCV" exact="infection" post="by modulating innate immune responseAntivir. Res.201815611612710.1016/j.antiviral.2018.05.01229906476 44.BadiaR.BallanaE.CastellvíM.García-VidalE.PujantellM.ClotetB.PradoJ.G.PuigJ.MartínezM.A.Riveira-MuñozE.et al.CD32 expression"/>
  <result pre="design and data analysis using the combination index methodAm. J." exact="Cancer" post="Res.201669710427073727 46.ChouT.C.TalalayP.Quantitative analysis of dose-effect relationships: The combined effects"/>
  <result pre="NVP, in wild-type (■) or SAMHD1-depleted (Δ) MDMs. Inhibition of" exact="HIV infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="in wild-type (■) or SAMHD1-depleted (Δ) MDMs. Inhibition of HIV" exact="infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="AraC in wild-type (■) or SAMHD1-depleted (Δ) MDM. Inhibition of" exact="HIV infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="in wild-type (■) or SAMHD1-depleted (Δ) MDM. Inhibition of HIV" exact="infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="treatments in wild-type (■) or SAMHD1-depleted (Δ) MDMs. Inhibition of" exact="HIV infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="in wild-type (■) or SAMHD1-depleted (Δ) MDMs. Inhibition of HIV" exact="infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="Palbociclib, in wild-type (■) or SAMHD1-depleted (Δ) MDM. Inhibition of" exact="HIV infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="in wild-type (■) or SAMHD1-depleted (Δ) MDM. Inhibition of HIV" exact="infection" post="was measured as the percentage of GFP+ cells relative"/>
  <result pre="indicated doses. Membranes were blotted with an anti phospho-SAMHD1 antibody," exact="total" post="SAMHD1, anti phosho-pRB and total pRB. Hsp90 antibody was"/>
  <result pre="with an anti phospho-SAMHD1 antibody, total SAMHD1, anti phosho-pRB and" exact="total" post="pRB. Hsp90 antibody was used as control. A representative"/>
  <result pre="the combination of palbociclib-pemetrexed measured as antiviral activity. Inhibition of" exact="HIV infection" post="with increasing doses of palbociclib and pemetrexed was measured."/>
  <result pre="combination of palbociclib-pemetrexed measured as antiviral activity. Inhibition of HIV" exact="infection" post="with increasing doses of palbociclib and pemetrexed was measured."/>
  <result pre="the combination of midostaurin-pemetrexed measured as antiviral activity. Inhibition of" exact="HIV infection" post="with increasing doses of midostaurin and pemetrexed was measured."/>
  <result pre="combination of midostaurin-pemetrexed measured as antiviral activity. Inhibition of HIV" exact="infection" post="with increasing doses of midostaurin and pemetrexed was measured."/>
  <result pre="Regulation of dNTP pool is responsible for drug synergy. (A)" exact="Protein" post="expression in MDMs treated with palbociclib (PD) at 1"/>
  <result pre="combination in vitro. Figure 7 Expression of SAMHD1 protein in" exact="tumor" post="samples from cancer patients. (A,B) IHC staining of SAMHD1"/>
  <result pre="Figure 7 Expression of SAMHD1 protein in tumor samples from" exact="cancer" post="patients. (A,B) IHC staining of SAMHD1 in pancreas (A)"/>
  <result pre="IHC staining of SAMHD1 in pancreas (A) and lung (B)" exact="tumor" post="samples. Morphology of tumor cells is shown by routine"/>
  <result pre="in pancreas (A) and lung (B) tumor samples. Morphology of" exact="tumor" post="cells is shown by routine hematoxylin stain of paraffin"/>
  <result pre="cells is shown by routine hematoxylin stain of paraffin embedded" exact="tumor" post="sections. SAMHD1 is stained in brown. Original magnification ×200."/>
  <result pre="Atlas (www.proteinatlas.org, IHC data of SAMHD1 expression from 17 different" exact="tumor" post="types were retrieved and classified according to protein expression"/>
  <result pre="or not SAMHD1. The values of EC50 were calculated in" exact="primary" post="MDMs untreated or transduced with HIV-2 Vpx that led"/>
 </snippets>
</snippetsTree>
